Yet the authors said this was the first study to their knowledge that specifically investigated the effect of DPP-4 inhibitor use on the incidence of IBD.
One previous observational study actually found a decreased risk of a composite outcome of several autoimmune disorders – including IBD – with the use of DPP-4 inhibitors, but it did not report on IBD specifically. The authors also noted that DPP-4 may have a different biological function in IBD.
The Canadian Institutes of Health Research funded the study. No conflicts of interest were declared.
SOURCE: Abrahami D et al. BMJ. 2018;360:k872.